A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg, 100 mg or Placebo When Coadministered With Rosuvastatin 10 mg or 20 mg in Subjects With Primary Hypercholesterolemia
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Lapaquistat (Primary) ; Rosuvastatin
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 19 Jan 2009 Status changed from discontinued to completed.
- 13 Jan 2009 Official title amended as reported by ClinicalTrials.gov.
- 28 Mar 2008 Status changed from in progress to discontinued. According to a Takeda media release, development of lapaquistat is being discontinued.